ReviewArchives of microbiology2025
Insights into the evolution of Candidalysin and recent developments.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Insights on molecular drivers of phenotypic plasticity in Candidozyma auris.World journal of microbiology & biotechnology · 2026Review
- Hemolytic Activity of VaginalPathogens (Basel, Switzerland) · 2026Article
- Gut microbiota-innate immune crosstalk in the initiation and progression of CRC: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- Perspectives on Vaginal Ecology and Management of Recurrent Vulvovaginal Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Dynamic expression of candidalysin facilitates oral colonization of Candida albicans in mice.Nature microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The alarming rise in fungal infections poses a serious health concern worldwide. Candida albicans is a highly virulent, ubiquitous opportunistic fungal pathogen associated with high mortality, particularly in immunocompromised individuals. Its infections range from superficial mucosal to invasive candidiasis. The pathogenicity of C. albicans is largely attributed to its ability to undergo phenotypic switching between different morphological forms ranging from unicellular to hyphae. A key factor in its pathogenesis is candidalysin, a fungal cytolytic peptide toxin. Candidalysin is generated through the expression of the ECE1 polyprotein, which, upon cleavage by the protease Kex2, yields both candidalysin and non-candidalysin ECE1-derived peptides. Notably, despite its critical role in virulence, the ECE1 gene is not widely conserved among fungal pathogens and is predominantly restricted to a few Candida species. This review highlights recent advances in understanding candidalysin-mediated cell damage and immune activation pathways, and also provides insights into the evolution of the ECE1 gene and its potential role in the coevolution of C. albicans with its human host.
Indexed as
Identifiers
40742540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.